Rusconi Stefano, Marcotullio Simone, Cingolani Antonella
Divisione Clinicizzata di Malattie Infettive, DIBIC Luigi Sacco, Università degli Studi di Milano, Italia.
On behalf of Nadir Onlus Board of Directors, Roma2, Italia.
New Microbiol. 2017 Apr;40(2):75-79. Epub 2017 Apr 3.
Current cART regimens are highly potent and well tolerated, but long-term toxicities, drug-drug interactions, lifetime costs and scarce option for multiclass failed patients could limit the efficacy of treatment itself. Long-acting formulations of antiretrovirals, which could potentially replace daily tablets, have been developed and are under investigation for prevention and treatment of HIV infection. Cabotegravir and rilpivirine represent the first drugs studied in this context. The aim of this review is to summarize the biological bases, the available information on completed and ongoing clinical trials and the potential development of long-acting regimens for the treatment and prevention of HIV infection.
目前的抗逆转录病毒治疗（cART）方案效力强大且耐受性良好，但长期毒性、药物相互作用、终身治疗成本以及多类药物治疗失败患者的选择有限，这些可能会限制治疗本身的疗效。已经开发出长效抗逆转录病毒制剂，有可能取代每日服用的片剂，目前正在进行预防和治疗HIV感染的研究。卡博特韦和rilpivirine是在此背景下研究的首批药物。本综述的目的是总结长效治疗方案在治疗和预防HIV感染方面的生物学基础、已完成和正在进行的临床试验的现有信息以及潜在发展情况。
